The effects of insulin-like growth factors on tumorigenesis and neoplastic growth

Endocrine Reviews

Volumn 21, Issue 3, 2000, Pages 215-244

  Khandwala, Hasnain M ^a   Mccutcheon, Ian E ^a   Flyvbjerg, Allan ^b   Friend, Keith E ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN ANTAGONIST; GROWTH HORMONE DERIVATIVE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; SOMATOSTATIN ANTIBODY; SOMATOSTATIN DERIVATIVE;

ANIMAL CELL; BONE TUMOR; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE GENITAL TRACT TUMOR; GASTROINTESTINAL TUMOR; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE GENITAL TRACT TUMOR; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN TUMOR; TUMOR GROWTH; UROGENITAL TRACT TUMOR;

EID: 0034453098     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.21.3.0399     Document Type: Review

References (260)

1. Insulin-like growth factors and their binding proteins: Biological actions
2. Insulin-like growth factors
3. Insulin-like growth factors
4. Insulin-like growth factor binding proteins and their role in controlling IGF actions
5. Functional role of the insulin-like growth factor binding proteins
6. Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily
7. The insulin-like growth factor-binding protein (IGFBP) superfamily
8. Insulin-like growth factor binding protein enhancement of insulin-like growth factor (IGF) mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line
9. Insulin-like growth factors and their receptors in growth
10. The insulin-like growth factor-I receptor protects tumor cells from apoptosis in vivo
11. Growth and differentiation signals by the insulin-like growth factor 1 receptor in hematopoietic cells are mediated through different pathways
12. Molecules in focus: Insulin-like growth factor II (IGF-II)
13. Type-2IGF receptor: A multi ligand binding protein
14. Decreased insulin-like growth factor-II/mannose-6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells
15. Normal growth and development in the absence of hepatic insulin-like growth factor-I
16. Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor I gene expression in the ovariectomized hypophysectomized rat
17. Hormonal regulation of insulin-like growth factor I secretion by bovine adrenal cells
18. Insulin-like growth factor I messenger ribonucleic acid expression in porcine thyroid follicles is regulated by thyrotropin and iodine
19. Reduction of immunoreactive somatomedin-C during fasting in humans
20. Structure, expression, and regulation of the IGF-I gene
21. Transcriptional and post-transcriptional regulation of the human IGF-II gene expression
22. Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors
23. Altered imprinting of the H19 and insulin-like growth factor II genes in testicular tumors
24. Loss of imprinting and overexpression of IGF2 gene in gastric adenocarcinoma
25. Regulation by fasting of insulin-like growth factor-I and its receptor. Effects on gene expression and binding
26. The regulation of insulin-like growth factor-I receptor gene expression by positive and negative zinc-finger transcription factors
27. Characterization of a specific receptor for somatomedin-C (SM-C) on cultured human lymphocytes: Evidence that SM-C modulates homologous receptor concentration
28. Regulation of insulin-like growth factor-I receptor gene expression by Sp1: Physical and functional interactions of Sp1 at GC boxes and at a CT element
29. Differential regulation of insulin-like growth factor-I (IGF-I) receptor gene expression by IGF-I and basic fibroblastic growth factor
30. Regulation of insulin-like growth factor-II P3 promoter by P53: A potential mechanism for tumorigenesis
31. The human cation-independent mannose-6-phosphate receptor. Cloning and sequence of the full length cDNA and expression of functional receptor in cos cells
32. Insulin-like growth factor-II/marmose-6-phosphate receptor is incapable of activating GTP-binding proteins in response to mannose-6-phosphate, but capable in response to insulin-like growth factor-II
33. Control of insulin-like growth factor-II/mannose-6-phosphate receptor gene transcription by proximal promoter elements
34. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities
35. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro
36. Octreotide
37. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I
38. Mechanism of antineoplastic action of somatostatin analogs
39. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSRT1 and SSRT2
40. Overexpression of human insulin-like growth factor-I receptor promotes ligand-dependent neoplastic transformation
41. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type I insulin-like growth factor receptor
42. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice
43. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect
44. Monoclonal antibodies to receptors for insulin and somato-medin-C
45. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor-I
46. Analysis of the inter action of insulin-like growth factor-I (IGF-I) analogs with the IGF-I receptor and IGF binding proteins
47. Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor-I receptors. The role of tyrosine residues 1250, 1251 and 1316 in the carboxy-terminus of the IGF-I receptor
48. The expression of insulin-like growth factor-I and insulin-like growth factor-II genes in the human fetal and adult brain and in glioma
49. Expression of insulin-like growth factors-I and II and their receptor mRNAs in primary human astrocytomas and meningiomas: In vivo studies using in situ hybridization and immunocytochemistry
50. Radioimmunoassay of insulin-like growth factors in cyst fluid of central nervous system tumors
51. Insulin and insulin-like growth factors in central nervous system tumors
52. Characterization of insulin-like growth factor-I in human primary brain tumors
53. Insulin-like growth factor-I content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas
54. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor-I RNA
55. Expression of insulin-like growth factors and their receptors in human meningiomas
56. Gene expression of insulin-like growth factor-II in human intracranial meningioma
57. Enhancement of insulin-like growth factor-II receptors in glioblastomas
58. Expression of two types of receptors for insulin-like growth factors in human glioma
59. Insulin and insulin-like growth factor-I in brain tumors: Binding and in vitro effects
60. Insulin-like growth factor-I receptors in human glial tumors
61. Mutant IGF-I receptors as dominant negatives for growth and transformation
62. The insulin-like growth factor-I receptor: A key to tumor growth?
63. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor-I receptors 1995
64. Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor-I receptor antisense mRNA
65. A soluble insulin-like growth factor-I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis
66. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-I (IGF-I) receptor are non-tumorigenic and induce regression of wild-type tumors
67. Differential expression of insulin-like growth factor-II in human meningiomas
68. A high ratio of insulin-like growth factor-II/IGFBP-2 mRNA as a marker for anaplasia in meningiomas
69. Characterization of insulin-like growth factor-I and epidermal growth factor receptors in meningioma
70. 125I-IGF-I binding to human meningiomas and on proliferation of meningioma cells
71. Growth hormone receptor expression and function in meningioma: Effect of a specific receptor antagonist
72. The growth hormone receptor antagonist, pegvisomant, inhibits the growth of human meningiomas xenografted into immunocompromised animals
73. Matrigel augments xenograft transplantation of meningioma cells into athymic mice
74. Intracranial injection of human meningioma cells in athymic mice: An orthotopic model for meningioma growth
75. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas
76. Simultaneous production of insulin-like growth factor-I and epidermal growth factor competing growth factors by HT-29 human colon cancer line
77. Abnormal expression and structural modification of the of insulin-like growth factor-II gene in human colorectal tumors
78. Expression of insulin-like growth factor-II and IGF-I receptor during proliferation and differentiation of CaCo-2 human colon carcinoma cells
79. Insulin-like growth factor-II expression in carcinoma in colon cell lines: Implications for autocrine actions
80. Expression of insulin-like growth factor-II can predict the prognosis of human colorectal cancer patients: Correlation with tumor progression, proliferative activity and survival
81. Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastasis from colorectal carcinoma
82. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon
83. Presence of somatomedin receptors on primary human breast and colon carcinomas
84. Expression of two types of receptor for insulin-like growth factors in human colonic epithelium
85. Characterization of insulin-like growth factor-I receptors in human colon cancer
86. Type I insulin-like growth factor receptors in human colorectal cancer
87. Insulin-like growth factor-I mRNA in the colon is unchanged during neoplasia
88. Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation
89. Episomal expression of sense and antisense insulin-like growth factor (IGF) binding protein-4 complimentary DNA alters the mitogenic response of a human colon cancer cell line (HT-29) by mechanisms that are in-dependent of and dependent upon IGF-I
90. Growth inhibition and differentiation of the human colon carcinoma cell line, Caco-2, by constitutive expression of insulin-like growth factor binding protein-3
91. Insulin and insulin-like growth factor-I stimulate proliferation of metastatic variants of colon carcinoma
92. Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor-I, II and transforming growth factor α
93. Blockade of insulin-like growth factor-I receptor inhibits growth of human colorectal cancer cells: Evidence of a functional IGF-II mediated autocrine loop
94. Effects of gastrin, proglumide and somatostatin on growth of human colon cancer
95. Somatostatin analogue RC-160 inhibits the growth of transplanted colon cancer in rats
96. Effects of pentagastrin and of the somatostatin analogue (SMS 201-995) on growth of CT26 in vivo adenocarcinoma of the colon
97. Treatment of liver metastasis of human colon cancers in nude mice with somatostatin analogue RC-160
98. SMS 201-995 inhibits in vitro and in vivo growth of human colon cancer
99. GH receptor antagonist treatment inhibits growth of human colorectal carcinoma, COLO205 in nude mice
100. Serum concentrations of insulin-like growth factor-I in colonic neoplasia
101. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor-I (IGF) and IGF binding protein-3
102. The effect of long-acting somatostatin analogue SMS 201-995 therapy on tumor kinetic measurements and serum tumor marker concentrations in primary rectal cancer
103. A randomized trial of octreotide vs. best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy
104. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma
105. Inhibition of tumor cell kinetics and serum insulin-like growth factor-I levels by octreotide in colorectal cancer patients
106. Autocrine regulation of human tumor cell proliferation by insulin-like growth factor-II: An in vitro model
107. Expression of c-sis platelet derived growth factor-B, insulin-like growth factor-I and transforming growth factor α messenger RNA and their respective receptor messenger RNA in primary human gastric carcinomas: In vivo studies with in situ hybridization and Immunocytochemistry
108. Insulin-like growth factor binding protein modulates the growth response to insulin-like growth factor-I by human gastric cancer cells
109. Co-stimulation of gastrointestinal tumor cell growth by gastrin, transforming growth factor α and insulin-like growth factor-I
110. Insulin-like growth factor-I and transforming growth factor α as autocrine growth factors in human pancreatic cancer cell growth
111. Insulin-like growth factor-I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles
112. Altered expression of insulin-like growth factor-II receptor in human pancreatic cancer
113. Effects of various growth factors on growth of a cloned human esophageal squamous cancer cell line in a protein-free medium
114. Overexpression of epidermal growth factor and insulin-like growth factor-I receptors and autocrine stimulation in human esophageal carcinoma cells
115. Evidence of autocrine regulation in human hepatoma cell lines
116. Transcripts of insulin-like growth factor-I and II in human hepatoma
117. Differential expression of insulin-like growth factor mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis
118. Localization of insulin-like growth factor-II and hepatitis B virus mRNA and proteins in human hepatocellular carcinomas
119. Expression of insulin-like growth factor-II in human hepatocellular carcinomas: An immunohistochemical study
120. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice
121. Characterization of insulin-like growth factor axis in a human hepatoma cell line (PLC)
122. Expression of insulin-like growth factor-II mRNA in hepatocellular carcinoma
123. Co-localization of insulin-like growth factor-II and the proliferation marker MIB1 in hepatocellular carcinoma cells
124. Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II
125. Evidence for an increased somatomedin-C/insulin-like growth factor-I content in primary human lung tumors
126. Evidence for autocrine mitogenic stimulation by somato-medin-C/insulin-like growth factor-I on an established human lung cancer cell line
127. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro
128. Production of immunoreactive Insulin-like growth factor-I and response to exogenous IGF-I in small cell lung cancer cell lines
129. Autocrine function for insulin-like growth factor-I in human small cell lung cancer cell lines and flesh tumor cells
130. Production of immunoreactive insulin-like growth factor (IGF)-I and IGF binding proteins by human lung tumors
131. Characterization of insulin-like growth factor-I receptors and growth effects in human lung cancer cell lines
132. Characterization of insulin-like growth factor-II receptors in human small cell lung cancer cell lines
133. Expression of insulin-like growth factor-I and IGF-II receptors in normal human lung and in lung cancer
134. Monoclonal antibody αIR3 inhibits non-small cell lung cancer growth in vitro and in vivo
135. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor-I receptor on human lung cancer cell lines
136. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type I IGF receptor
137. In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue
138. Response of human lung tumor xenografts with a somatostatin analogue (Somatuline)
139. Effects of somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice
140. Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer
141. Phase I study of the somatostatin analogue somatuline in refractory small-cell lung carcinoma
142. Phase II study of high dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer
143. Insulin-like growth factor-I: Autocrine secretion by human thyroid follicular cells in primary culture
144. Immunoreactive insulin-like growth factor (IGF)-I and IGF binding protein content in human thyroid tissue
145. Autocrine role of insulin-like growth factor-I in a human thyroid cancer cell line
146. Expression of insulin-like growth factor receptors in primary human thyroid neoplasms
147. Insulin-like growth factor-II/mannose-6-phosphate receptors are increased in primary human thyroid neoplasms
148. Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graveś-IgG
149. Secretion of an insulin-like growth factor-I related protein by human breast cancer cells
150. Analysis of insulin-like growth factor-I gene expression in malignancy: Evidence for a paracrine role in human breast cancer
151. Expression of IGF-I and IGF-II mRNA in breast tissue
152. mRNA expression of the components of the insulin-like growth factor system in breast cancer cell lines, tissues and metastatic breast cancer cells
153. Insulin-like growth factor-II: A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor
154. Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture
155. Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture
156. Characterization of insulin-like growth factor-I receptors of human breast cancer cells
157. Demonstration of insulin-like growth factor (IGF)-I and IGF-II receptors and binding protein in human breast cancer cell lines
158. Type I IGF receptor in human breast diseases
159. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: Correlation with estrogen receptor status
160. Estrogen and antiestrogen modulation of MCF7 breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor binding proteins in conditioned media
161. Insulin-like growth factor binding protein-3 (IGFBP-3) inhibits estrogen-stimulated breast cancer cell proliferation
162. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein-3 autocrine loop in human breast cancer cells
163. Insulin-like growth factor (IGF)-independent actions of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition
164. Insulin-like growth factor binding protein-3 induces apoptosis in MCF-7 breast cancer cells
165. Insulin-like growth factor binding protein 3 (IGFBP-3) production by MCF-7 breast cancer cells: Stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol
166. Insulin-like growth factor binding protein 3 mediates retinoic acid and transforming growth factor β2-induced growth inhibition in human breast cancer cells
167. Insulin-like growth factor binding protein 3 (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner
168. Insulin-like growth factor binding protein-1 expression inhibits insulin-like growth factor-I action in MCF-7 breast cancer cells
169. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice
170. An antibody to the receptor for insulin-like growth factor receptor-I inhibits the growth of MCF-7 cells in tissue culture
171. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β-estradiol
172. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somato-medin receptor
173. Blockade of type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice
174. Role of insulin-like growth factor and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells
175. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells
176. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-DMBA induced rat mammary carcinomas
177. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation
178. Enhancement of tamoxifen induced suppression of insulin-like growth factor-I gene expression and serum level by a somatostatin analogue
179. Plasma insulin-like growth factor-I concentrations in human breast cancer
180. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
181. Effects of tamoxifen on serum insulin-like growth factor-I levels in stage I breast cancer patients
182. Effect of the long acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer
183. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue in the treatment of advanced breast cancer
184. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: Clinical activity and effect on insulin-like growth factor-I levels
185. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer
186. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma
187. Expression of insulin-like growth factor-I, its binding proteins, and its receptors in ovarian cancer
188. Insulin-like growth factor-I and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines
189. Insulin-like growth factor (IGF)-I and IGF binding protein-2 are increased in cyst fluids of epithelial ovarian cancer
190. Biological characterization of human epithelial ovarian carcinoma cells in primary culture: The insulin-like growth factor system
191. Identification of insulin and insulin-like growth factor-I receptors in ovarian cancer tissue
192. Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen
193. Increased insulin-like growth factor binding protein 2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid
194. Elevated serum insulin-like growth factor binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor
195. Antisense phophorothioate oligodeoxynucleotide down-regulation of the insulin-like growth factor-I receptor in ovarian cancer cells
196. The insulin-like growth factor I receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression
197. Regulation of endometrial cancer cell growth by insulin-like growth factors and the leutinizing hormone-releasing hormone antagonist SB-75
198. Expression of insulin-like growth factors and their binding proteins in the estrogen responsive Ishikawa human endometrial cancer cell line
199. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins
200. Transforming growth factor α and insulin-like growth factor-I, but not epidermal growth factor elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines
201. The effects of tamoxifen on endometrial insulin-like growth factor-I expression
202. Insulin-like growth factor-I receptors in normal and neoplastic human endometrium
203. Suppressed expression of insulin-like growth factor binding protein-I mRNA in the endometrium: A molecular mechanism associating endometrial cancer with its risk factors
204. Modulation of insulin-like growth factor-I (IGF-I) receptors and membrane associated IGF-binding proteins in endometrial cancer cells by estradiol
205. Mitogenic activity of growth factors in the human endometrial adenocarcinoma cell lines HEC-1-A and KLE
206. Overexpression of insulin-like growth factor-I receptor and autocrine stimulation in human cervical cancer cells
207. Epidermal growth factor suppresses insulin-like growth factor binding protein-3 levels in human papillomavirus type-16 immortalized cervical epithelial cells and thereby potentiates the effects of insulin-like growth factor-I
208. Insulin-like growth factors (IGFs), IGF receptors and IGF binding proteins in primary cultures of prostate epithelial cells
209. Insulin-like growth factor-I and IGFBPs: Stimulatory and inhibitory factors secreted by human prostate adenocarcinoma cells
210. Inhibition of growth of prostate cancer cell lines by peptide analogues of insulin-like growth factor-I
211. Insulin-like growth factor-I: Action and receptor characterization in human prostate cancer cell lines
212. Regulation of DU 145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop
213. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and the IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3)
214. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of the mouse prostate (TRAMP) model
215. Protein and messenger RNA for the type I insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium
216. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor-II in tumors
217. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: Evidence for an IGF-II autocrine growth loop
218. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation
219. Castration induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor binding proteins
220. Somatostatin analogs as adjuncts to agonists of leutinizing hormone-releasing hormone in the treatment of experimental prostate cancer
221. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin
222. Effects of microcapsules of leutenizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model
223. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate cancer xenografts in nude mice
224. Somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice
225. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
226. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone
227. Insulin-like growth factor-I in relation to prostate cancer and benign prostatic hyperplasia
228. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
229. Insulin-like growth factor-I and prostate cancer risk: A population based, casecontrol study
230. Therapeutic response to somatostatin analogue BIM 23014 in metastatic prostate cancer
231. A phase I study of the somatostatin analogue somatuline in patients with metatstatic hormone-refractory prostate cancer
232. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer
233. Insulin-like growth factors and the multiplication of Tera-2, a human teratoma-derived cell line
234. Human teratocarcinoma cells express functional insulin-like growth factor-I receptors
235. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma
236. Dietary restriction reduces insulin-like growth factor-I levels which modulates apoptosis, cell proliferation, and tumor progression in p53-defident mice
237. The growth hormone: Insulin-like growth factor-I axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats
238. Human osteosarcoma (U-2OS) cells express both insulin-like growth factor (IGF)-I receptors and IGF-II receptors and synthesize IGF-II: Autocrine growth stimulation by IGF-II via the IGF receptor
239. Expression of insulin-like growth factor receptor, IGF-I and IGF-II in primary and metastatic osteosarcoma
240. Insulin-like growth factor-I: A potent mitogen for human osteogenic sarcoma
241. Human osteosarcoma cell lines are dependent on insulin-like growth factor-I for in vitro growth
242. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy
243. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone
244. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice
245. Demonstration of receptors for insulin and insulin-like growth factors on Swarm rat chondrosarcoma chondrocytes
246. Insulin-like growth factor-I and II are autocrine factors in stimulating proteoglycan synthesis, a marker of differentiated chondrocytes, acting through their respective receptors on a clonal human chondrosarcoma-derived chondrocyte cell line, HCS-2/8
247. Insulin-like growth factor-I regulation of Swarm rat chondrosarcoma chondrocytes in culture
248. Stimulation of tumor growth by recombinant human insulin-like growth factor (IGF)-I is dependent on the dose and the level of IGF-I receptor expression
249. Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors
250. Effects of insulin-like growth factor receptor inhibition on human melanomas in culture and in athymic mice
251. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type I insulin-like growth factor receptor
252. Insulin-like growth factors are mitogenic for human keratinocytes and a squamous cell carcinoma
253. Overexpression of insulin-like growth factor-I induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice
254. Enhancement of susceptibility to diverse skin tumor promoters by activation of insulin-like growth factor-I receptor in the epidermis of transgenic mice
255. Human leukemic cells: Receptor binding and biological effects of insulin and insulin-like growth factors
256. Characterization of insulin, insulin-like growth factor-I and II and growth hormone receptors on human leukemic lymphoblasts
257. Receptor binding and mitogenic effects of insulin and insulin-like growth factor-I and II for human myeloid leukemic cells
258. Effects of insulin and insulin-like growth factor-I on growth of human leukemia cells in serum-free and protein-free medium
259. Human growth hormone and insulin-like growth factor-I enhance the proliferation of human leukemic blasts
260. Long R-3 insulin-like growth factor-I (IGF-I) stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentration in guinea pigs